NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,537.81 +223.95 (+1.22%) CRUDE OIL
79.03 +0.04 (+0.05%) GOLD FUTURES
2,339.90 +17.60 (+0.76%) DOW
39,303.72 +247.33 (+0.63%) Bitcoin GBP
49,504.89 -495.70 (-0.99%)
Simcere Pharmaceutical Group Ltd (S2P.MU)
- PR Newswire
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.
- GlobeNewswire
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
Simcere has been granted an exclusive right to develop, manufacture, and commercialize rademikibart for all indications in Greater ChinaConnect Biopharma retains rights to develop and commercialize rademikibart in all other markets and completed the pivotal atopic dermatitis (AD) trial in ChinaRademikibart is a human monoclonal antibody against IL-4Rα, a common subunit for IL-4R and IL-13 receptors being developed for the treatment of Th2 driven inflammatory diseases SAN DIEGO, CA and TAICANG, C
- Business Wire
Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham
CAMBRIDGE, Mass., June 12, 2023--Simcere Pharmaceutical Group Limited (2096.HK) (Simcere) announced a Sponsored Research Agreement with Mass General Brigham. With more than 80,000 employees, 13 Nobel laureates and an annual research budget of $2 billion, Mass General Brigham is one of the largest and most prestigious academic medical centers in the United States. Under the agreement up to eight research groups at Mass General Brigham will be funded on select projects over the course of two years
